Jaw Clenching
Bluelighter
- Joined
- Feb 4, 2005
- Messages
- 551
Jensen, Niels: Tryptamines as Ligands and Modulators of the Serotonin 5‑HT2A Receptor and the Isolation of Aeruginascin from the Hallucinogenic Mushroom Inocybe aeruginascens
Abstract
Aeruginascin is a natural product from the hallucinogenic mushroom Inocybe aeruginascens. This compound was isolated and identified as 4-phosphoryloxy-N,N,N-trimethyltryptamine. Aeruginascin is the quaternary trimethylammonium analog of the hallucinogenic compound psilocybin. Synthetic aeruginascin was identical in all aspects to the isolated sample. Additionally, the mushroom alkaloids norbaeocystin and baeocystin were synthesized and a new synthetic approach to 4‑hydroxy-tryptamines was investigated.
In a related project the influence of N-terminal substituents of tryptamines on serotonin receptor binding was studied. A series of tryptamines carrying a broad range of structurally diverse amino-substituents was synthesized. Most compounds had binding affinities in the nanomolar range for the 5‑HT1A, the 5‑HT2A, and the 5‑HT2C receptor. In functional 5‑HT2A IP accumulation assays most ligands acted as antagonists or partial agonists. Several compounds had biphasic dose-response curves. Sometimes the response at higher concentrations exceeded even that of the natural agonist serotonin. As shown by additional experiments, this effect was probably caused by non-competitive positive allosteric modulation of the 5‑HT2A receptor at higher concentrations. These results indicate a new independent regulatory binding site of the 5‑HT2A receptor. In contrast to a previous publication, in our hands the lead compound N‑(4‑bromobenzyl)-5‑methoxy_tryptamine was a low-affinity antagonist at the 5‑HT2A receptor.
Abstract
Aeruginascin is a natural product from the hallucinogenic mushroom Inocybe aeruginascens. This compound was isolated and identified as 4-phosphoryloxy-N,N,N-trimethyltryptamine. Aeruginascin is the quaternary trimethylammonium analog of the hallucinogenic compound psilocybin. Synthetic aeruginascin was identical in all aspects to the isolated sample. Additionally, the mushroom alkaloids norbaeocystin and baeocystin were synthesized and a new synthetic approach to 4‑hydroxy-tryptamines was investigated.
In a related project the influence of N-terminal substituents of tryptamines on serotonin receptor binding was studied. A series of tryptamines carrying a broad range of structurally diverse amino-substituents was synthesized. Most compounds had binding affinities in the nanomolar range for the 5‑HT1A, the 5‑HT2A, and the 5‑HT2C receptor. In functional 5‑HT2A IP accumulation assays most ligands acted as antagonists or partial agonists. Several compounds had biphasic dose-response curves. Sometimes the response at higher concentrations exceeded even that of the natural agonist serotonin. As shown by additional experiments, this effect was probably caused by non-competitive positive allosteric modulation of the 5‑HT2A receptor at higher concentrations. These results indicate a new independent regulatory binding site of the 5‑HT2A receptor. In contrast to a previous publication, in our hands the lead compound N‑(4‑bromobenzyl)-5‑methoxy_tryptamine was a low-affinity antagonist at the 5‑HT2A receptor.